HTS Molecules Targeting APP 5'untranslated Region(RMI)
HTS Molecules Targeting APP 5'untranslated Region(RMI)
批准号:
7407177
负责人:
JACK T ROGERS
金额:
$4.38万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-30 至 2008-08-31
关键词:
5&apos Untranslated RegionsAlzheimer&aposs DiseaseAmyloidAmyloid beta-ProteinAmyloid beta-Protein PrecursorAnimalsAntibioticsAzithromycinBindingBiologicalBiological AssayBrainCell LineCellsChelating AgentsCollaborationsConditionDataDeferoxamineDevelopmentDown SyndromeDrug Delivery SystemsDrug DesignElementsEnhancersEquipmentErythromycinFerritinFigs - dietaryGelGenesGenomeHIVHIV InfectionsHomeostasisHourInitiator CodonInterleukin-1IronIron-Regulatory ProteinsLaboratoriesLibrariesLuciferasesMessenger RNAMetalloproteinsModelingMusNerve DegenerationNeuroblastomaNew AgentsOutputParoxetinePathologyPathway interactionsPatientsPeptidesPharmaceutical PreparationsPilot ProjectsPreclinical Drug EvaluationProductionProtein BiosynthesisProteinsRNARNA SequencesRNA-Protein InteractionRegulationRegulatory ElementRelative (related person)ReporterReportingRibosomal RNARibosomesScreening procedureSenile PlaquesStandards of Weights and MeasuresStructureTarsTestingTherapeuticTimeTranscriptTransfectionTransferrin ReceptorTransgenic OrganismsTranslationsUnited States Food and Drug AdministrationUntranslated RegionsWestern Blottingbaseconceptdensitydrug discoveryexperiencehigh throughput screeningin vivoinhibitor/antagonistmRNA Stabilitymouse modelpreventprotein expressionresearch studysmall moleculestable cell linetherapeutic targettissue culturetool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The 5'untranslated region of the mRNAforthe Alzheimer's Amyloid Precursor Protein (APP 5'UTR) is a key
translational regulatory element that sets the amount of APP production in any given cell. IL-1 enhanced the
interaction between Iron-regulatory Proteins (IRPs) and APP 5'UTR RNA secondary structure via an Iron-
responsive Element (IRE). This regulation suggested the APP 5'UTR to be an excellent drug target.
Our laboratory gained valuable experience in the field of drug discovery when we screened a library of FDA-
pre-approved drugs and identified 17 leads that limited APP 5'UTR driven translation using transiently
transfected neuroblastoma cells. In secondary western blot-based assays paroxetine (SSRI) and
dimercaptopropanol (chelator) selectivley reduced APP holoprotein expression. As proof of drug selectivity
achieved during the APP 5'UTR screen these two hits did not change APLP-1 and APLP-2 expression in
SH-SY5Y cells (Payton et al.,2003). A pilot study indicated that Paroxetine reduced the amyloid burden in a
transgenic mouse model for AD (TgCRNDS mice).
The data to be gathered through this R03 RFA mechanism will assist us to develop our FDA pilot screen to
set up a high throughput transfection based screen of an important RNA target. Use of automated
equipment for 384 well based screens is now available through our collaboration with the Laboratory of Drug
Discovery for Neurodegenreration (LDDN). Our strategy will be to optimize a high throughput screen of the
110,000 compounds in the LDDN drug library to identify new agents that selectively inhibit translation driven
by the APP 5'UTR enhancer. These leads may well provide downstream therapeutic anti-amyloid limiting
action. Use of our drug hits in RNA gel-shift and APP expression based experiments will probe the
pathway of APP translation. IRP-1 and IRP-2 post-transcriptionally control iron homeostasis by modulating
ferritin translation and transferrin receptor mRNA stability. HTS hits directed to the 146 nt APP 5'UTR will
provide new tools to assess precisely the importance of the interaction of IRP-1 and IRP-2 with 5'UTR of the
mRNA encodiing APP (metalloprotein), relative to the mRNAs of other key iron proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Post Transcriptional Control of hemorrhagic iron damage.
-
批准号:8383920
-
项目类别:
-
资助金额:$25.02万
-
财政年份:2012
-
负责人:JACK T ROGERS
-
依托单位:
Post Transcriptional Control of hemorrhagic iron damage.
-
批准号:8489367
-
项目类别:
-
资助金额:$20.77万
-
财政年份:2012
-
负责人:JACK T ROGERS
-
依托单位:
RNA Targeted Screens of the Prion 5'UTR
-
批准号:7617517
-
项目类别:
-
资助金额:$17.59万
-
财政年份:2008
-
负责人:JACK T ROGERS
-
依托单位:
RNA Targeted Screens of the Prion 5'UTR
-
批准号:8112177
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2008
-
负责人:JACK T ROGERS
-
依托单位:
RNA Targeted Screens of the Prion 5'UTR
-
批准号:8112178
-
项目类别:
-
资助金额:$4.4万
-
财政年份:2008
-
负责人:JACK T ROGERS
-
依托单位:
MLSN Screen of the PD Alpha Synuclein 5'UTR
-
批准号:7680767
-
项目类别:
-
资助金额:$4.38万
-
财政年份:2007
-
负责人:JACK T ROGERS
-
依托单位:
MLSN Screen of the PD Alpha Synuclein 5'UTR
-
批准号:7290548
-
项目类别:
-
资助金额:$21.88万
-
财政年份:2007
-
负责人:JACK T ROGERS
-
依托单位:
HTS Molecules Targeting APP 5'untranslated Region(RMI)
-
批准号:7021329
-
项目类别:
-
资助金额:$8.75万
-
财政年份:2005
-
负责人:JACK T ROGERS
-
依托单位:
RNA Therapeutics and Abeta Precursor Protein Translation
-
批准号:6773195
-
项目类别:
-
资助金额:$29.37万
-
财政年份:2003
-
负责人:JACK T ROGERS
-
依托单位:
RNA Therapeutics and Abeta Precursor Protein Translation
-
批准号:7116896
-
项目类别:
-
资助金额:$28.68万
-
财政年份:2003
-
负责人:JACK T ROGERS
-
依托单位:
RNA Therapeutics and Abeta Precursor Protein Translation
-
批准号:6617387
-
项目类别:
-
资助金额:$31.79万
-
财政年份:2003
-
负责人:JACK T ROGERS
-
依托单位:
RNA Therapeutics and Abeta Precursor Protein Translation
-
批准号:6930498
-
项目类别:
-
资助金额:$29.37万
-
财政年份:2003
-
负责人:JACK T ROGERS
-
依托单位:
COREGULATION OF APP AND FERRITIN MRNAS AND APP FUNCTION
-
批准号:2758833
-
项目类别:
-
资助金额:$8.48万
-
财政年份:1998
-
负责人:JACK T ROGERS
-
依托单位:
TRANSLATIONAL CONTROL OF THE ACUTE PHASE RESPONSE
-
批准号:3456128
-
项目类别:
-
资助金额:$11.74万
-
财政年份:1992
-
负责人:JACK T ROGERS
-
依托单位:
TRANSLATIONAL CONTROL OF THE ACUTE PHASE RESPONSE
-
批准号:3456129
-
项目类别:
-
资助金额:$11.88万
-
财政年份:1992
-
负责人:JACK T ROGERS
-
依托单位:
TRANSLATIONAL CONTROL OF THE ACUTE PHASE RESPONSE
-
批准号:2067598
-
项目类别:
-
资助金额:$11.41万
-
财政年份:1992
-
负责人:JACK T ROGERS
-
依托单位:
TRANSLATIONAL CONTROL OF THE ACUTE PHASE RESPONSE
-
批准号:2067600
-
项目类别:
-
资助金额:$12.83万
-
财政年份:1992
-
负责人:JACK T ROGERS
-
依托单位:
TRANSLATIONAL CONTROL OF THE ACUTE PHASE RESPONSE
-
批准号:2067599
-
项目类别:
-
资助金额:$12.34万
-
财政年份:1992
-
负责人:JACK T ROGERS
-
依托单位:
海外基金